Welcome to our dedicated page for Agilent Technologies SEC filings (Ticker: A), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agilent Technologies Inc. filings document financial reporting and governance matters for an analytical and clinical laboratory technology company. Form 8-K reports include quarterly financial-result releases, Regulation FD disclosures, non-GAAP measure explanations, executive officer transitions, compensatory arrangements and amendments to charter and bylaws.
Proxy and annual-meeting filings cover director elections, stockholder voting, executive compensation, equity awards and the phased declassification of the board. The records also identify governance changes tied to the company’s Delaware certificate of incorporation and bylaws, together with furnished press releases and related exhibits.
Agilent Technologies is asking stockholders to vote at its 2026 annual meeting on electing four directors, approving executive pay on an advisory basis, ratifying PricewaterhouseCoopers as auditor, and amending its certificate of incorporation to declassify the board over three years. If the declassification proposal passes, all directors would stand for annual elections beginning in 2029.
The proxy outlines a largely independent board, an independent chair, majority voting for directors, proxy access, and policies against hedging, short selling and pledging company stock. It highlights ongoing shareholder engagement, including outreach to holders of about 65% of shares and broad support for declassifying the board after a 2025 stockholder proposal.
The filing also reviews director and CEO-level compensation structures, emphasizing pay-for-performance with most executive pay “at risk,” use of annual and long‑term incentives tied to revenue, margins, EPS and relative total shareholder return, and changes to the CFO role in 2025 with related transition and sign‑on awards.
Agilent Technologies, Inc. reported an amendment to an insider ownership filing for its vice president and corporate controller. The officer’s directly held common stock was corrected to 32,153.3546 shares following previously reported transactions. The original report had shown 31,526.6872 shares, so this amendment adds back shares that were understated due to an administrative error. The company states that only the holdings total is revised and that there are no changes to the underlying transactions previously reported.
Agilent Technologies, Inc. files its annual report describing a global business focused on life sciences, diagnostics and applied markets. The company provides instruments, software, services and consumables that support the entire laboratory workflow, serving pharmaceutical, biopharmaceutical, diagnostics, clinical, academic, government, chemical, food, environmental and forensics customers.
In November 2024 Agilent reorganized into three reportable segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets, and recast historical segment data to match this structure. Life Sciences and Diagnostics Markets combines liquid chromatography and mass spectrometry platforms with diagnostics, genomics, cell analysis and specialty contract development and manufacturing services, including BIOVECTRA and nucleic acid solutions.
Agilent CrossLab provides services, consumables, software and automation that are largely vendor neutral, while Applied Markets focuses on instruments and software for chemical, energy, advanced materials, food and environmental testing. As of October 31, 2025, Agilent employed approximately 18,100 people worldwide, with major R&D and manufacturing sites across the U.S., Europe and Asia.
Agilent Technologies director reports stock sale. A director of Agilent Technologies, Inc. reported selling 2,600 shares of common stock on 12/01/2025 at a weighted average price of $149.812 per share, with individual sale prices ranging from $149.80 to $149.84. After this transaction, the director beneficially owns 4,973.028 shares of Agilent common stock. This total includes 23.092 shares acquired through the company’s dividend reinvestment plan in transactions exempt under Rule 16a-11, which the director has elected to defer.
Agilent Technologies’ senior vice president reported a routine share transaction related to equity compensation. On 11/26/2025, the executive surrendered 208 shares of Agilent common stock to the company at a price of $154.37 per share to cover tax withholding on vesting restricted stock units, as allowed under Rule 16b-3. After this tax-related share surrender, the reporting person beneficially owned 11,639.0318 shares of Agilent common stock directly.
Agilent Technologies, Inc. reported an insider equity transaction by a Senior Vice President. On 11/26/2025, the executive surrendered 280 shares of common stock to Agilent to satisfy tax liabilities arising from the vesting of restricted stock units, as permitted under Rule 16b-3. The shares were valued at $154.37 each for this tax withholding transaction.
After this event, the executive beneficially owned 26,593.9266 shares of Agilent common stock directly and 2,607.6856 shares indirectly through a spouse. This is an administrative tax-related transaction rather than an open-market purchase or sale.
Agilent Technologies, Inc. reported an insider transaction by its President and CEO, who is also a director. On 11/26/2025, the executive surrendered 1,948 shares of common stock to Agilent at $154.37 per share to cover tax liabilities arising from the vesting of restricted stock units under Rule 16b-3.
After this tax-related share surrender, the executive beneficially owns 66,539 shares of Agilent common stock in direct ownership. This filing reflects a routine administrative transaction to satisfy taxes rather than an open-market sale.
Agilent Technologies, Inc. officer and Senior Vice President reported a routine equity transaction on Form 4. On 11/26/2025, the reporting person surrendered 300 shares of Agilent common stock to the company at a price of $154.37 per share to cover tax liabilities arising from the vesting of restricted stock units under Rule 16b-3. After this tax-related surrender, the reporting person beneficially owned 14,207.2469 shares of Agilent common stock, held directly.
Agilent Technologies executive reports small stock disposition for tax withholding
A Senior Vice President of Agilent Technologies, Inc. reported a routine share disposition related to equity compensation. On 11/26/2025, the executive surrendered 430 shares of Agilent common stock at a reported price of $154.37 per share, coded as an "F" transaction, meaning the shares were withheld to cover taxes on vesting restricted stock units. After this transaction, the executive beneficially owns 14,262 shares of Agilent common stock directly. No derivative securities transactions were reported in this filing.
Agilent Technologies executive Rodney Gonsalves, Vice President and Corporate Controller, reported multiple stock transactions in Agilent Technologies, Inc. common stock. On 11/26/2025, he sold 3,000 shares at a weighted average price of $154.9853 per share, with individual sale prices ranging from $154.98 to $155.05. He also surrendered 119 shares to Agilent to cover tax liabilities related to the vesting of restricted stock units.
That same day, Gonsalves reported several gift-related movements: transfers coded as gifts involving 200 shares connected to the Gonsalves Family Charitable Gift Fund and indirect holdings in the Gonsalves Trust. After these transactions, he directly owned 31,526.6872 shares of Agilent common stock and held 40.192 shares indirectly through the Gonsalves Trust.